For example, one study shows that EIF4E(+)/cyclin D1(−) NSCLC patients have poorer clinical outcome, while EIF4E(−)/cyclin D1(+) patients have a more favorable outcome, and patients with EIF4E(+)/cyclin D1(+) have an intermediate outcome [15]. The gene discussed is CCND1; the disease is non-small cell lung carcinoma.